Genetic polymorphism in metabolism and host defense enzymes: Implications for human health risk assessment

Critical Reviews in Toxicology

Volumn 40, Issue 7, 2010, Pages 575-619

  Ginsberg, Gary ^a   Guyton, Kathryn ^b   Johns, Douglas ^b   Schimek, Jennifer ^c   Angle, Kenneth ^d   Sonawane, Babasaheb ^b  

^a CDC   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c RTI INTERNATIONAL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Epoxide hydrolase; glucuronosyltransferases; NADPH quinone:oxidoreductase; pharmacodynamics; pharmacokinetics; SNPs; sulfotransferases; XRCC1

Indexed keywords

CYCLOOXYGENASE 2; EPOXIDE HYDROLASE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; GLYCEROL 3 PHOSPHATE DEHYDROGENASE (NAD); HYDROXYTAMOXIFEN; MINOXIDIL; MYCOPHENOLIC ACID; PARACETAMOL; PRASTERONE; PROPOFOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SALICYLAMIDE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DIPHOSPHATE; URIDINE DIPHOSPHOGLUCURONOSYLTRANSFERASE;

ANTIOXIDANT ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER RISK; CELLULAR IMMUNITY; COLORECTAL CANCER; CONJUGATION; DETOXIFICATION; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DRUG ACTIVATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME METABOLISM; ESTROGEN METABOLISM; ETHNICITY; FEASIBILITY STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; GILBERT DISEASE; HEALTH HAZARD; HOST RESISTANCE; HUMAN; HYDROLYSIS; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MOLECULAR EPIDEMIOLOGY; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; NULL ALLELE; ONTOGENY; PROSTATE CANCER; PROTEIN STABILITY; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SULFONATION; XENOBIOTIC METABOLISM;

ENZYMES; HUMANS; POLYMORPHISM, GENETIC; PUBLIC HEALTH; RISK ASSESSMENT; XENOBIOTICS;

EID: 77954876634     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408441003742895     Document Type: Review

References (347)

1. Abdel-Rahman SZ, El-Zein RA, Ammenheuser MM, Yang Z, Stock TH, Morandi M, Ward JB Jr. (2003). Variability in human sensitivity to 1,3-butadiene: Infuence of the allelic variants of the microsomal epoxide hydrolase gene. Environ Mol Mutagen 41:140-146.
2. Abdel-Rahman SZ, Ammenheuser MM, Omiecinski CJ, Wicklife JK, Rosenblatt JI, Ward JB Jr. (2005). Variability in human sensitivity to 1,3-butadiene: Infuence of polymorphisms in the 5'-fanking region of the microsomal epoxide hydrolase gene (EPHX1). Toxicol Sci 85:624-631.
3. Ada AO, Suzen HS, Iscan M. (2007). Polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1 in a male Turkish population. Int J Toxicol 26:41-46.
4. Adegoke OJ, Shu XO, Gao YT, Cai Q, Breyer J, Smith J, Zheng W. (2004). Genetic polymorphisms in uridine diphospho-glucuronosyltrans-ferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 85:239-245. (Pubitemid 38987258)
5. Alam SN, Roberts RJ, Fischer LJ. (1977). Age-related diferences in salicylamide and acetaminophen conjugation in man. J Pediatr 90:130-135.
6. Alcorn J, McNamara PJ. (2002). Ontogeny of hepatic and renal systemic clearance pathways in infants, part 1. Clin Pharmacokinet 41:959-998. (Pubitemid 35168438)
7. Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera M-E, et al. (2001). Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 61:2542-2546.
8. Allegaert K, ?e Hoon J, Verbesselt R, Vanhole C, Devlieger H, Tibboel D. (2005). Intra-and interindividual variability of glucuronidation of paracetamol during repeated administration of propacetamol in neonates. Acta Paediatr 94:1273-1279.
9. Alnouti Y, Klaassen CD. (2008). Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. J Pharmacol Exp Ter 324:612-621.
10. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y. (2006). Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255-1259.
11. Arand M, Cronin A, Adamska M, Oesch F. (2005). Epoxide hydrolases: Structure, function, mechanism, and assay. Methods Enzymol 400:569-588.
12. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. (2001). Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA 98:1188-1193.
13. Asher G, Bercovich Z, Tsvetkov P, Shaul Y, Kahana C. (2005). 20S proteosomal degredation of ornithine decarboxylase is regulated by NQO1. Mol Cell 17:645-655.
14. Asher G, Dym O, Tsvetkov P, Adler A, Shaul Y. (2006). Te crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry 45:6372-6378
15. Bag A, Bag N. (2008). Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: A review. Cancer Epidemiol Biomarker Prevent 17:3298-3305.
16. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D. (2007). C-440T/T-331C polymorphisms in the UGT1A9 gene afect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8:1127-1141.
17. Bánhegyi G, Garzó T, ?ntoni F, Mandl J. (1988). Glycogenolysis and not glu-coneogenesis is the source of UDP-glucuronic acid for glucuronidation. Biochem Biophys Acta 967:429-435.
18. Basu NK, Kovarova M, Garza A, Kubota S, Saha T, Mitra PS, Banerjee R, Rivera J, Owens IS. (2005). Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specifcity. Proc Natl Acad Sci USA 102:6285-6290.
19. Begleiter A, Norman A, Leitao D, Cabral T, Hewitt D, Pan S, Grandis JR, Siegfried JM, El-Sayed S, Sutherland D, Ross DA, Kerr PD. (2005). Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol 41:927-933.
20. Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. (2003). Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 14:473-479.
21. Bergamaschi E, De Palma G, Mozzoni P, Vanni S, Vettori MV, Broeckaert F, Bernard A, Mutti A. (2001). Polymorphism of quinone-metabolizing enzymes and susceptibility to ozone-induced acute efects. Am J Respir Crit Care Med 163:1426-1431.
22. Bergamo P, Maurano F, Rossi M. (2007). Phase 2 enzyme induction by conjugated linoleic acid improves lupus-associated oxidative stress. Free Radic Biol Med 43:71-79.
23. Berlin I, de Brettes B, Aymard G, Diquet B, Arnulf L, Puech AJ. (2000). Dopaminergic drug response and the genotype (Taq IA polymorphism) of the dopamine D2 receptor. Int J Neuropsychopharmacol 3:35-43.
24. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. (2006). Infuence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophe-nolic acid. Drug Metab Dispos 34:1539-1545.
25. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO. (2000). Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7)?at amino acid 268: Ethnic diversity of alleles and potential clinical signifcance. Pharmacogenetics 10:679-685.
26. Bian HS, Ngo SY, Tan W, Wong CH, Boelsterli UA, Tan TM. (2007). Induction of human sulfotransferase 1A3 (SULT1A3) by glucocorticoids. Life Sci 81:1659-1667.
27. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD (2001). CYP2C9 and UGT1A6 genotypes modulate the protective efect of aspirin on colon adenoma risk. Cancer Res 61:3566-3569.
28. Binkova B, Chvatalova I, Lnienickova Z, Milcova A, Tulupova E, Farmer PB, Sram RJ. (2007). PAH-DNA adducts in environmentally exposed populations in relation to metabolic and DNA repair gene polymorphisms. Mutat Res 620:49-61. (Pubitemid 46776723)
29. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, Lazarus P. (2009). Functional signifcance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 69:1892-1900.
30. Boccia S, Persiani R, La Torre G, Rausei S, Arzani D, Gianfagna F, Romano-Spica V, D Ugo D, Ricciardi G. (2005). Sulfotransferase 1A1 polymorphism and gastric cancer risk: A pilot case-control study. Cancer Lett 229:235-243.
31. Bolufer P, Collado M, Barragan E, Cervera J, Calasanz MJ, Colomer D, Roman-Gomez J, Sanz MA (2007). Te potential efect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haemotologica 92:308-314.
32. Boogaard PJ, van Sittert NJ. (1996). Suitability of S-phenyl mercapturic acid and trans,trans-muconic acid as biomarkers for exposure to low concentrations of benzene, Environ Health Perspect 104:1151-1157.
33. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, et al. (1995). Te genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert s syndrome. N Engl J Med 333:1171-1175.
34. Braun L, Kardon T, Puskás F, Csala M, Bánhegyi G, Mandl J. (1997). Regulation of glucuronidation by glutathione redox state through the alteration of UDP-glucose supply originating from glycogen metabolism. Arch Biochem Biophys 348:169-173.
35. Brauze D, Widerak M, Cwykiel J, Szyfter K, Baer-Dubowska W. (2006). Te efect of aryl hydrocarbon receptor ligands on the expression of AhR, AhRR, ARNT, Hif1alpha, CYP1A1 and NQO1 genes in rat liver. Toxicol Lett 167:212-220.
36. Bray BJ, Rosengren RJ. (2001). Retinol potentiates acetaminophen-induced hepatotoxicity in the mouse: Mechanistic studies. Toxicol Appl Pharmacol 173:129-136.
37. Breast Cancer Association Consortium. (2006). Commonly studied single-nucleotide polymorphisms and breast cancer: Results From the Breast Cancer Association Consortium. J Natl Cancer Inst 98:1382-1396.
38. Buda G, Maggini V, Galimberti S, Barale R, Rossi AM, Petrini M. (2007). NQO1*2 polymorphism and response to treatment in patients with multiple myeloma. Leukemia Res 31:1029-1030. (Pubitemid 46876688)
39. Bufngton GD, Ollinger K, Brunmark A, Cadenas E. (1989). DT-diaphorase-catalysed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Efect of substituents on autoxidation rates. Biochem J 257:561-571.
40. Burchell B, Coughtrie MW. (1989). UDP-glucuronosyltransferases. Pharmacol Ter 43:261-289.
41. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. (2001). Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 22:593-597.
42. Butler LM, Duguay Y, Millikan RC, Sinha R, Gagné JF, Sandler RS, Guillemette C. (2005). Joint efects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:1626-1632.
43. Cappiello M, Giuliani L, Pacifci GM. (1991). Distribution of UDP-glucuronosyltransferase and its endogenous substrate uridine-5'- diphosphoglucuronic acid in human tissues. Eur J Clin Pharmacol 41:345-350.
44. Carpenter SL, Lief S, Howard TA, Eggleston B, Ware RE. (2008). UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia. Am J Hematol 83:800-803.
45. Celli CM, Trana N, Knox R, Jaiswala AK. (2006). NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 72:366-376.
46. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. (2005). Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 97:457-460.
47. Chang JL, Bigler J, Schwarz Y, Li SS, Li L, King IB, Potter JD, Lampe JW. (2007). UGT1A1 polymorphism is associated with serum bilirubin concentrations in a randomized, controlled, fruit and vegetable feeding trial. J Nutr 137:890-897.
48. Chao C, Zhang ZF, Berthiller J, Bofetta P, Hashibe M. (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: A meta-analysis. Cancer Epidemiol Biomarkers Prev 15:979-987.
49. Chen G, Dellinger RW, Sun D, Spratt TE, Lazarus P. (2008). Glucuronidation of tobacco-specifc nitrosamines by UGT2B10. Drug Metab Dispos 36:824-830.
50. Chen S, Beaton D, Nguyen N, Senekeo-Efenberger K, Brace-Sinnokrak E, Argikar U, Remmel RP, Trottier J, Barbier O, Ritter JK, Tukey RH. (2005). Tissue-specifc, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280:37547-3757.
51. Cheng SL, Yu CJ, Chen CJ, Yang PC. (2004). Genetic polymorphism of epox-ide hydrolase and glutathione S-transferase in COPD. Eur Respir J 23:818-824.
52. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, Han W, Kim JS, Shin SG, Jang IJ, Yoo KY, Hirvonen A, Kang D. (2005). Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1090-1095. (Pubitemid 40656452)
53. Chouinard S, Yueh MF, Tukey RH, Giton F, Fiet J, Pelletier G, Barbier O, Bélanger A. (2008). Inactivation by UDP-glucuronosyltransferase enzymes: Te end of androgen signaling. J Steriod Biochem Mol Biol 109:247-253.
54. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG. (2005). Efect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ter 77:486-494.
55. Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ. (2008). Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ter 83:595-600.
56. Chung JK, Yuan W, Liu G, Zheng J. (2006). Investigation of bioactivation and toxicity of styrene in CYP2E1 transgenic cells. Toxicology 226:99-106.
57. Ciotti M, Marrone A, Potter C, Owens IS. (1997). Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: Pharmacological implications. Pharmacogenetics 7:485-495.
58. Clement FC, Dip R, Naegeli H. (2007). Expression profle of human cells in culture exposed to glycidamide, a reactive metabolite of the heat-induced food carcinogen acrylamide. Toxicology 240:111-124.
59. Cortessis V, Siegmund K, Chen Q, Zhou N, Diep A, Frankl H, Lee E, Zhu QS, Haile R, Levy D. (2001). A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res 61:2381-2385.
60. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ. (2002). Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuro-nidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 30:1257-1265.
61. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ. (2004). UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ter 310:656-665.
62. Covarrubias VG, Lakhman SS, Forrest A, Relling MV, Blanco JG. (2006). Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett 164:249-258.
63. Cullen, JJ, Hinkhouse, MM, Grady, M, Gaut, AW, Liu, J, Zhang, YP, Darby Weydert, CJ, Domann, FE, Oberley LW. (2003). Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res 63:5513-5520.
64. Daly AK. (1995). Molecular basis of polymorphic drug metabolism. J Mol Med 73:539-553.
65. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. (2008). UGT2B7 promoter variant-840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 83:200-202.
66. Dash B, Afriyie-Gyawu E, Huebner HJ, Porter W, Wang JS, Jolly PE, Phillips TD. (2007). Determinants of the variability of afatoxin-albumin adduct levels in Ghanaians. J Toxicol Environ Health Part A 70:58-66.
67. Dekant W, Volkel W. (2008). Human exposure to bisphenol A by biomonitor-ing: Methods, results and assessment of environmental exposures. Toxicol Appl Pharmacol 228:114-134.
68. Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. (2006). Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxifcation of polycyclic aromatic hydrocarbons: Decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 34:943-949.
69. Demchuk EB, Yucesoy VJ, Johnson MA, Weston DR, Germolec CT, Luster MI. (2007). A statistical model for assessing genetic susceptibility as a risk factor in multifactorial diseases: Lessons from occupational asthma. Environ Health Perspect 115:231-234.
70. Dogliotti E. (2006). Molecular mechanisms of carcinogenesis by vinyl chloride. Annali dell Istituto superiore di sanità 42:163-169.
71. Douidar SM, Ahmed AE. (1987). A novel mechanism for the enhancement of acetaminophen hepatotoxicity by phenobarbital. J Pharmacol Exp Ter 240:578-583.
72. Dousa MK, Weinshilboum RM, Muenter MD, Oford KP, Decker PA, Tyce GM. (2003). l-DOPA biotransformation: Correlations of dosage, erythro-cyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients. J Neural Transm 110:899-910.
73. Duanmu Z, Weckle A, Koukouritaki SB, Hines RN, Falany JL, Falany CN, Kocarek TA, Runge M. (2006). Developmental expression of aryl, estrogen and hydroxysteroid sulfotransferases in pre-and post-natal human liver. J Pharmacol Exp Ter 316:1310-1317.
74. Duguay Y, Báár C, Skorpen F, Guillemette C. (2004a). A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with signifcant impact on promoter activity. Clin Pharmacol Ter 75:223-233.
75. Duguay Y, McGrath M, Lépine J, Gagné JF, Hankinson SE, Colditz GA, Hunter DJ, Plante M, Têtu B, Bélanger A, Guillemette C, De Vivo I. (2004b). Te functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 64:1202-1207.
76. DuTeaux SB, Newman JW, Morisseau C, Fairbairn EA, Jelks K, Hammock BD, Miller MG. (2004). Epoxide hydrolases in the rat epididymis: Possible roles in xenobiotic and endogenous fatty acid metabolism. Toxicol Sci 78:187-195.
77. Erichsen TJ, Ehmer U, Kalthof S, Lankisch TO, Müller TM, Munzel PA, Manns M P, Strassburg C P. (2008). Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP-glucuronosyltransferase (UGT)1A4 gene. Toxicol Appl Pharmacol 230:252-260.
78. Eugster HP, Sengstag C, Hinnen A, Meyer UA, Würgler FE. (1991). Heterologous expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae. Study of the valpromide-carbamazepine epoxide interaction. Biochem Pharmacol 42:1367-1372.
79. Falany CN, Wheeler J, Oh TS, Falany JL. (1994). Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 48:369-375.
80. Falany JL, Falany CN. (1997). Regulation of estrogen activity by sulfation in human MCF-7 breast cancer cells. Oncol Res 9:589-596.
81. Falany JL, Pillof DE, Leyh TS, Falany CN. (2006). Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos 34:361-368.
82. Fang JL, Lazarus P. (2004). Correlation between the UDP- glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxifcation phe-notype: Signifcantly decreased glucuronidating activity against benzo(a) pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 13:102-109.
83. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, Lazarus P. (2002). Characterization of benzo(a)pyrene-trans-7,8-dihy-drodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978-1986.
84. Fang X. (2006). Soluble epoxide hydrolase: A novel target for the treatment of hypertension. Recent Patents Cardiovasc Drug Discov 1:67-72.
85. Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, Tardon A, Serra C, Carrato A, Garcia-Closas R, Vinyals GC, Rothman N, Garcia Clonas M. (2007). Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet 121:233-242.
86. Fleming RA, Drees J, Loggie BW, Russell GB, Geisinger KR, Morris RT, Sachs D, McQuellon RP. (2002). Clinical signifcance of a NAD(P)H:quinine oxi-doreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mito-mycin C. Pharmacogen 12:31-37.
87. Forbes-Bamforth KJ, Coughtrie MW. (1994). Identifcation of a new adult human liver sulfotransferase with specifcity for endogenous and xeno-biotic estrogens. Biochem Biophys Res Commun 198:707-711.
88. Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W. (2004). Oral contraceptive use and breast cancer risk: Modifcation by NAD(P)H:quinone oxore-ductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 13:1308-1315.
89. Freimuth RR, Ecklof B, Wieben ED, Weinshilboum RM. (2001). Human sul-fotransferase SULT1C? pharmacogenetics: Gene resequencing and functional genomic studies. Pharmacogen 11:745-746.
90. Fretland AJ, Omiecinski CJ. (2000). Epoxide hydrolases: Biochemistry and molecular biology. Chem Biol Interact 129:41-59.
91. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. (2002). Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
92. Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, Lazarus P. (2007a). Te UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case control study in Caucasians. Cancer Detect Prev 31:310-315.
93. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, Chase GA, Richie J, Lazarus P. (2007b). Te UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: Sex-specifc association with urinary 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 16:823-828.
94. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. (2006). Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-22.
95. Gelotte CK, Auiler JF, Lynch JM, Temple AR, Slattery JT. (2007). Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin Pharmacol Ter 81:840-848.
96. Gharavi N, El-Kadi AO. (2007). Role of nitric oxide in downregulation of cyto-chrome P450 1A1 and NADPH:quinone oxidoreductase 1 by tumor necrosis factor-alpha and lipopolysaccharide. J Pharm Sci 96:2795-2807.
97. Gibbs TT, Russek SJ, Farb DH. (2006). Sulfated steroids as endogenous neuro-modulators. Pharmacol Biochem Behav 84:555-567.
98. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M. (2002a). Evaluation of child/adult pharmacokinetic diferences from a database derived from the therapeutic drug literature. Toxicol Sci 66:185-200.
99. Ginsberg G, Smolenski S, Hattis D, Sonawane B. (2002b). Population distribution of aldehyde dehydrogenase-2 genetic polymorphism: Implications for risk assessment. Regul Toxicol Pharmacol 36:297-309.
100. Ginsberg G, Neafsey P, Hattis D, Guyton K, Johns D, Sonawane B. (2009a). Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity. J Toxicol Environ Health Part B 12:473-507.
101. Ginsberg G, Smolenski S, Hattis D, Guyton K, Johns D, Sonawane B. (2009b). Genetic polymorphism in glutathione transferases (GSTs): Population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health Part B 12:389-439.
102. Ginsberg G, Smolenski S, Neafsey P, Hattis D, Walker K, Guyton K, Johns D, Sonawane B. (2009c). Analysis of the infuence of genetic polymorphisms on inter-individual variability in xenobiotic metabolism for six enzyme systems. J Toxicol Environ Health Part B 12:307-333.
103. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA. (2008). Efects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56-61.
104. Glatt H. (2000). Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 129:141-70.
105. Gsur A, Zidek T, Schnattinger K, Feik E, Haidinger G, Hollaus P, Mohn-Staudner A, Armbruster C, Madersbacher S, Schatzl G, Trieb K, Vutuc C, Micksche M. (2003). Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer 89:702-706.
106. Gu SY, Zhang ZB, Wan JX, Jin XP, Xia ZL. (2007). Genetic polymorphisms in CYP1A1, CYP2D6, UGT1A6, UGT1A7? and SULT1A1 genes and correlation with benzene exposure in a Chinese occupational population. J Toxicol Environ Health A 70:916-924.
107. Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE, Hunter DJ. (2001). Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 10:711-714.
108. Guillemette C, Millikan RC, Newman B, Housman DE. (2000a). Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60:950-956.
109. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. (2000b). Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: Functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
110. Gulyaeva LF, Mikhailova ON, PustyInyak VO, Kim IV, Gerasimov AV, Krasilnikov SE, Filipenko ML, Pechkovsky E V. (2008). Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endome-trial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 617:359-366.
111. Han DF, Zhou X, Hu MB, et al. (2004). Sulfotransferase 1A1 (SULT1A1) polymorphism and breast cancer risk in Chinese women. Toxicol Lett 150:167-177.
112. Han JY, Lim HS, Shin ES, Yoo YK, Park YH. (2006). Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinote-can and cisplatin. J Clin Oncol 24:2237-2244.
113. Hang J, Zhou W, Wang X, Zhang H, Sun B, Dai H, Su L, Christiani DC. (2005). Microsomal epoxide hydrolase, endotoxin, and lung function decline in cotton textile workers. Am J Respir Crit Care Med 171:165-170.
114. Hanioka N, Naito T, Narimatsu S (2008). Human UDP-glucronosyltransferase isoforms involv?d in bisphenol A glucuronidation. Chemosphere 74:33-36.
115. Hanson SR, Best MD, Wong CH. (2004). Sulfatases: Structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed Engl 2004;43:5736-5763.
116. Hassett C, Alcher L, Sidhu JS, Omiecinski CJ. (1994). Human microsomal epox-ide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3:421-428.
117. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. (1997). Human hepatic microsomal epoxide hydrolase: Comparative analysis of polymorphic expression. Arch Biochem Biophys 337:275-283.
118. He JQ, Ruan J, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. (2002). Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am J Respir Crit Care Med 166:323-328.
119. Hildebrandt MA, Salavaggione OE, Martin YN, Flynn HC, Jalal S, Wieben ED, Weinshilboum RM. (2004). Human SULT1A3 pharmacogenetics: Gene duplication and functional genomic studies. Biochem Biophys Res Commun 321:870-878
120. Hildebrandt M, Carrington DP, Tomae BA, Ecklof BW, Schaid DJ, Yee VC, Weinshilboum RM. Wieben ED. (2007). Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogen J 7:133-143.
121. Hinson JP, Brooke A, Raven PW. (2003). Terapeutic uses of dehydroepiandros-terone. Curr Opin Investig Drugs 4:1205-1208.
122. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, Rabban JT, Chen LM, Dahiya R. (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 112:1964-1973.
123. Hochstein P. (1983). Futile redox cycling: Implications for oxygen radical toxic-ity. Fundam Appl Toxicol 3:215-217.
124. Hoelzl C, Glatt H, Meinl W, Sontag G, Haidinger G, Kundi M, Simic T, Chakraborty A, Bichler J, Ferk F, Angelis K, Nersesyan A, Knasmüller S. (2008). Consumption of Brussels sprouts protects peripheral human lymphocytes against 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyrid-ine (PhIP) and oxidative DNA-damage: Results of a controlled human intervention trial. Mol Nutr Food Res 52:330-341.
125. Hofman GR, Preston RJ. (2003). Genetic toxicology. In: Klaassen CD, Watkins JB III, eds. Casarett & Doull s Essentials of Toxicology. New York: McGraw-Hill 321-350.
126. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O, Kaasa S, Krokan HE, Skorpen F. (2002). Morphine glucuronide-to-morphine plasma ratios are unafected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58:353-356.
127. Hori H, Ohmori O, Matsumoto M, Shinkai T, Nakamura N. (2003). NAD(P) H:quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia. Psychiatry Res 118:235-239.
128. Hosagrahara VP, Rettie AE, Hassett C, Omiecinski CJ. (2004). Functional analysis of human microsomal epoxide hydrolase genetic variants. Chem Biol Interact 150:149-159.
129. Hu R, Shen G, Yerramilli UR, Lin W, Xu C, Nair S, Kong AN. (2006). In vivo phar-macokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice. Arch Pharmacol Res 29:911-920.
130. Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, Schoen RE, Hou LF, Berndt SI, Yadavalli S, Johnson CC, Hayes RB. (2005). Microsomal epox-ide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev 14:152-157. (Pubitemid 40165296)
131. Huang WY, Gao YT, Rashid A, Sakoda LC, Deng J, Shen MC, Wany BS, Han TQ, Zhang BH, Chen BE, Rosenberg PS, Chanock SJ, Hsing AW. (2008). Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: A population-based case-control study in China. Carcinogenesis 29:100-105.
132. Huber WW, Rossmanith W, Grusch M, Haslinger E, Prustomersky S, Peter-Vörösmarty B, Parzefall W, Scharf G, Schulte-Hermann R. (2008). Efects of cofee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol 46:1230-1238.
133. Hui Y, Yasuda S, Liu MY, Wu YY, Liu MC. (2008). On the sulfation and methyla-tion of catecholestrogens in human mammary epithelial cells and breast cancer cells. Biol Pharmacol Bull 31:769-773.
134. Hutt AM, Kalf GF. (1996). Inhibition of human DNA topoisomerase II by hydro-quinone and p-benzoquinone, reactive metabolites of benzene. Environ Health Perspect 104(Suppl 6):1265-1269.
135. Ieiri I, Takane H, Hirota T, Otsubo K and Higuchi S (2006). Genetic polymorphisms of drug transporters: Pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol 2:651-674.
136. Infante-Rivard C, Vermunt JK, Weinberg CR. (2007). Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia. Am J Epidemiol 165:1248-1254.
137. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388.
138. Iskander K, Gaikwad A, Paquet M, Long DJ 2nd, Brayton C, Barrios R, Jaiswal AK. (2005). Lower induction o? p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res 65:2054-2058.
139. Iskander K, Li J, Han S, Zheng B, Jaiswal AK. (2006). NQO1 and NQO2 regulation of humoral immunity and autoimmunity. J Biol Chem 281:30917-30924.
140. Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y. (2004). Six novel UDP-glucuronosyltranferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 49:123-128.
141. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ. (1999). Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ter 65:576-582.
142. Jamieson D, Wilson K, Pridgeon S, Margetts JP, Edmondson RJ, Leung HY, Knox R, Boddy AV. (2007). NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:Quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clin Cancer Res 13:1584-1590.
143. Jiang J, Zhang X, Yang H, Wang W. (2009). Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology. Methods Mol Biol 471:305-333.
144. Jin CJ, Miners CO, Lillywhite KJ, Mackenzie PI. (1993). cDNA cloning and
145. Johnson WW, Yamazaki H, Shimada T, Ueng YF, Guengerich FP. (1997). Afatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase. Chem Res Toxicol 10:672-676.
146. Jones AL, Hagen M, Coughtrie MW, Roberts RC, Glatt H. (1995). Human platelet phenolsulfotransferases: cDNA cloning,?stable expression in V79 cells and identifcation of a novel allelic variant of the phenol-sulfating form. Biochem Biophys Res Commun 208:855-862.
147. Joseph P, Jaiswal AK. (1998). NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones. Br J Cancer 77:709-719.
148. Juchau MR, Fantel AG, Harris C, Beyer BK. (1986). Te potential role of redox cycling as a mechanism for chemical teratogenesis. Environ Health Perspect 70:131-136.
149. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, et al. (2005). Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab Dispos 33:458-465.
150. Kedderis GL. (1997). Extrapolation of in vitro enzyme induction data to humans in vivo. Chem Biol Interact 107:109-121.
151. Kelly EJ, Erickson KE, Sengstag C, Eaton DL. (2002). Expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae reveals a functional role in afatoxin B1 detoxifcation. Toxicol Sci 65:35-42.
152. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, Wang M, Xu X, Lee BK, Schwartz BS, Wiencke JK. (1997). Ethnic variation in the prevalence of a commonNAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer 76:852-854.
153. Khor VK, Tong MH, Qian Y, Song WC. (2008). Gender-specifc expression and mechanism of regulation of estrogen sulfotransferase in adipose tissues of the mouse. Endocrinology 149:5440-5448.
154. Kifmeyer WR, Langer E, Davies SM, Envall J, Robison LR, Ross JA (2004). Genetic polymorphisms in the Hmong population: Implications for cancer etiology and survival. Cancer 100:411-417.
155. Kim S, Lan Q, Waidyanatha S, Chanock S, Johnson BA, Vermeulen R, Smith MT, Zhang L, Li G, Shen M, Yin S, Rothman N, Rappaport SM. (2007). Genetic polymorphisms and benzene metabolism in humans exposed to a wide range of air concentrations. Pharmacogen Genomics 17:789-801.
156. Kitteringham NR, Davis C, Howard N, Pirmohamed M, Park BK. (1996). Interindividual and interspecies variation in hepatic microsomal epox-ide hydrolase activity: Studies with cis-stilbene oxide, carbamazepine 10,11-epoxide and naphthalene. J Pharmacol Exp Ter 1996;278:1018-1027.
157. Kiyohara C, Takayama K, Nakanishi Y. (2006a). Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: A meta-analysis. Lung Cancer 54:267-83.
158. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. (2006b). EPHX1 polymorphisms and the risk of lung cancer: A HuGE review. Epidemiology 17:89-99.
159. Koyama H, Geddes DM. (1998). Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease. Torax 53(Suppl 2):S10-S14.
160. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH. (2005a). UDP glucuronosyltransferase (UGT) 1A6 pharmacoge-netics: I. Identifcation of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ter 313:1331-1339.
161. Kuehl GE, Bigler J, Potter JD, Lampe JW. (2006). Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos 34:199-202.
162. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. (2005). Te impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ter 78:351-361.
163. Lafon B, Pérez-Cadahía B, Pásaro E, Méndez J. (2003). Individual sensitivity to DNA damage induced by styrene in vitro: Infuence of cytochrome p450, epoxide hydrolase and glutathione S-transferase genotypes. Toxicology 186:131-141.
164. Lampe JW, Bigler J, Bush AC, Potter JD. (2000). Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y) and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev 9:329-333.
165. Lanciotti M, Dufour C, Corral, L, Di Michele P, Pigullo S, De Rossi G, Basso G, et al. (2005). Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 19:214-216.
166. Landi L, Fiorentini D, Galli MC, Segura-Aguilar J, Beyer, RE (1997). DT-Diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function. Free Radic Biol Med. 22:329-335.
167. Lankisch TO, Vogel A, Eilermann S, Fiebeler A, Krone B, Barut A, Manns MP, Strassburg CP. (2005). Identifcation and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 67:1732-1739.
168. Lankisch TO, Gillman TC, Erichsen TJ, Ehmer U, Kalthof S, Freiberg N, Munzel PA, Manns MP, Strassburg CP. (2008a). Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene. Arch Toxicol 82:573-582.
169. Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V, Strassburg CP. (2008b). Gilbert s syndrome and irinotecan toxicity: Combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 17:695-701.
170. Larson AM. (2007). Acetaminophen hepatotoxicity. Clin Liver Dis 11:525-548.
171. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, Smith MT. (1999). Prevalence of the inactivating 609C->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94:803-807.
172. Laurenzana EM, Hassett C, Omiecinski CJ. (1998). Post-transcriptional regulation of human microsomal epoxide hydrolase. Pharmacogenetics 8:157-67.
173. Lebailly P, Willett EV, Moorman AV, Roman E, Cartwright R, Morgan GJ, Wild CP. (2002). Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defned cytogenetic abnormalities. Br J Haematol 116:587-594.
174. Lee CH, Ito Y, Yanagiba Y, Yamanoshita O, Kim H, Zhang SY, Kamijima M, Gonzalez FJ, Nakajima T. (2007). Pyrene-induced CYP1A2 and SULT1A1 may be regulated by CAR and not by AhR. Toxicology 5;238:147-56.
175. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. (2006). Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: Te Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15:1640-1649.
176. Lee WJ, Brennan P, Bofetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L, Taioli E. (2002). Microsomal epoxide hydrolase polymorphisms and lung cancer risk: A quantitative review. Biomarkers 7:230-241. (Pubitemid 34678838)
177. Leng S, Dai Y, Niu Y, Pan Z, Li X, Cheng J, He F, Zheng Y. (2004). Efects of genetic polymorphisms of metabolic enzymes on cytokinesis-block micronu-cleus in peripheral blood lymphocyte among coke-oven workers. Cancer Epidemil Biomarkers Prev 13:1631-1639.
178. Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, Guillemette C. (2004). Specifcity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89:5222-5232.
179. Lévesque E, Beaulieu M, Green MD, Tephly TR, Bélanger A, Hum DW. (1997). Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7:317-325.
180. Lévesque E, Beaulieu M, Hum DW, Bélanger A. (1999). Characterization and substrate specifcity of UGT2B4 (E458): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 9:207-216.
181. Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C. (2007). Te impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profle of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ter 81:392-400.
182. Levy G, Khanna NN, Soda DM, Tsuzuki O, Stern L. (1975). Pharmacokinetics of acetaminophen in the human neonate: Formation of acetaminophen glucuronide and sulphate in relation to plasma bilirubin concentration and d-glucaric acid excretion. Pediatrics 55:818-825.
183. Lewis SJ, Cherry NM, Niven RM, Barber P V, Povey AC. (2001). Polymorphisms in the NAD(P)H:quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 34:177-183.
184. Li G, Yin S. (2006). Progress of epidemiological and molecular epidemiological studies on benzene in China. Ann N Y Acad Sci 1076:800-809.
185. Li Y, Lee S, Marion MJ, Brandt-Rauf PW. (2005). Polymorphisms of microsomal epoxide hydrolase in French vinyl chloride workers. Int J Occ Med Environ Health 18:133-138. (Pubitemid 41039323)
186. Liang SH, Hassett C, Omiecinski CJ. (2005). Alternative promoters determine tissue-specifc expression profles of the human microsomal epoxide hydrolase gene (EPHX1). Mol Pharmacol 67:220-230.
187. Limenta LM, Jirasomprasert T, Tankanitlert J, Svasti S, Wilairat P, Chantharaksri U, Fucharoen S, Morales NP. (2008). UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol. 65:908-916.
188. Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, Xiang CQ, Ma QW, Lu DR, Shen JH. (2005). An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 85:502-506.
189. Lincz LF, Scorgie FE, Robertson R, Enno A. (2007). Genetic variations in benzene metabolism and susceptibility to multiple myeloma. Leuk Res 31:759-763.
190. Lindsay J, Wang LL, Li Y, Zhou SF. (2008). Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 9:99-105.
191. Lipscomb J, Kedderis G. (2002). Incorporating human interindividual biotransformation variance in health risk assessment. Sci Total Environ 288:13-21.
192. Lodovici M, Luceri C, Guglielmi F, Bacci C, Akpan V, Fonnesu ML, Boddi V, Dolara P. (2004). Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol Biomaker Prev 13:1342-1348.
193. Long DJ, Waikel RL, Wang XJ, Perlaky L, Roop DR, Jaiswal AK. (2000). NAD(P)H:quinone oxidoreductase 1 defciency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 60:5913-5915.
194. Long DJ, Gaikwad A, Multani A, Pathak S, Montgomery CA, Gonzalez FJ, Jaiswa AK. (2002). Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 62:3030-3036.
195. Lucier GW, Sonawane BR, McDaniel OS. (1977). Glucuronidation and deglu-curonidation reactions in hepatic and extrahepatic tissues during perinatal development. Drug Metab Dispos 5:279-287.
196. Manini P, De Palma G, Andreoli R, Mozzoni P, Poli D, Goldoni M, Petyx M, Apostoli P, Mutti A. (2010). Occupational exposure to low levels of benzene: Biomarkers of exposure and nucleic acid oxidation and their modulation by polymorphic xenobiotic metabolizing enzymes. Tox Lett 193:229-235.
197. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996). Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert s syndrome. Lancet 347:578-581.
198. Mulhall A, de Louvois J, Hurley R. 1983. Chloramphenicol toxicity in neonates: Its incidence and prevention. Br Med J (Clin Res Ed) 287:1424-1427.
199. Nagar S, Remmel RP. (2006). Uridine diphosphoglucuronosyltransferase phar-macogenetics and cancer. Oncogene 25:1659-1672.
200. Nagar S, Zalatoris JJ, Blanchard RL. (2004). Human UGT1A6 pharmacogenetics: Identifcation of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14:487-499.
201. Nagar S, Walther S, Blanchard RL. (2006). Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Molec Pharmacol 69:2084-2092.
202. Nakajima Y, Saito Y, Shiseki K, Fukushima-Uesaka H, Hasegawa R, Ozawa S, Sugai K, Katoh M, Saitoh O, Ohnuma T, Kawai M, Ohtsuki T, Suzuki C, Minami N, Kimura H, Goto Y, Kamatani N, Kaniwa N, Sawada J. (2005). Haplotype structures of EPHX1 and their efects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol 61:25-34.
203. Nakamura Y, Suzuki T, Sasano H. (2005). Estrogen actions and in situ synthesis in human vascular smooth muscle cells and their correlation with atherosclerosis. J Steroid Biochem Mol Biol 93:263-268.
204. Navarro SL, Peterson S, Chen C, Makar KW, Schwarz Y, King IB, Li SS, Li L, Kestin M, Lampe JW. (2009). Cruciferous vegetable feeding alters UGT1A1 activity: Diet and genotype-dependent changes in serum bilirubin in a controlled feeding trial. Cancer Prev Res 2:298-300.
205. Neafsey P, Ginsberg G, Hattis D, Sonawane B. (2009a). Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health Part B 12:334-361.
206. Neafsey P, Ginsberg G, Hattis D, Johns D, Guyton K, Sonawane B. (2009b). Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J Toxicol Environ Health Part B 12:362-388.
207. Nebert DW, Dalton TP. (2006). Te role of cytochrome P450 enzymes in endogenous signaling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947-960.
208. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. (2002). NAD(P) H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: A HuGE review. Genet Med 4:62-70.
209. Newman JW, Morisseau C, Hammock BD. (2005). Epoxide hydrolases: Teir roles and interactions with lipid met?bolism. Prog Lipid Res 44: 1-51.
210. Nishimura M, Koeda A, Shimizu T, Nakayama M, Satoh T, Narimatsu S, Naito S. (2008). Comparison of inducibility of sulfotransferase and UDP-glucuronosyltransferase mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepa-tocytes. Drug Metab Pharmacokinet 23:45-53.
211. Nowell S, Falany CN. (2006). Pharmacogenetics of human cytosolic sulfotrans-ferases. Oncogene 25:1673-1688.
212. Nowell S, Ambrosone CB, Ozawa S, MacLeod SL, Mrackova G, Williams S, Plaxco J, Kadlubar F F, Lang NP. (2000). Relationship of phenol sulfotrans-ferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogen 10:789-797.
213. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB. (2002). Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94:1635-1640.
214. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB. (2005). Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258.
215. Ogata N, Matsushima N, Shibata T. (1995). Pharmacokinetics of wood creosote: Glucuronic acid and sulfate conjugation of phenolic compounds. Pharmacology 51:195-204.
216. Ohno S, Nakajin S (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
217. Ohtake E, Kakihara F, Matsumoto N, Ozawa S, Ohno Y, Hasegawa S, Suzuki H, ?ubota T. (2006). Frequency distribution of phenol sulfotransferase 1A1 activity in platelet cells from healthy Japanese subjects. Eur J Pharm Sci 28:272-277.
218. Al Omari A, Murry DJ. (2007). Pharmacogenetics of the cytochrome P450 enzyme system: Review of current knowledge and clinical signifcance. J Pharm Pract 20:206-218.
219. Omiecinski CJ, Hassett C, Hosagrahara V. (2000). Epoxide hydrolase\Polymor-phism and role in toxicology. Toxicol Lett 112-113:365-370.
220. Onyenwoke RU, Wiegel J. (2007). Iron (III) reduction: A novel activity of the human NAD(P)H:oxidoreductase. Biochem Biophys Res Commun 353:389-393.
221. Orzechowski A, Schwarz LR, Schwegler U, Bock KW, Snyder R, Schrenk D. (1995). Benzene metabolism in rodent hepatocytes: Role of sulphate conjugation. Xenobiotica 25:1093-1102.
222. Ozawa S, Tang YM, Yamazoe Y, Kato R, Lang NP, Kadlubar FF. (1998). Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact 109:237-248.
223. Pacifci GM. (2004). Inhibition of human liver and duodenum sulfotrans-ferases by drugs and dietary chemicals: A review of the literature. Int J Clin Pharmacol Ter 42:488-495.
224. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. (2004). Infuence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44:854-860.
225. Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S, Helal M, Pow-Sang J. (2004). Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 171:2484-2488.
226. Park J, Chen L, ?atnashinge L, Sellers TA, Tanner JP, Lee JH, Dossett N, Lang N, Kadlubar FF, Ambrosone CB, Zachariah B, Heysek R V, Patterson S, Pow-Sang J. (2006). Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 15:1473-1478.
227. Park JY, Chen L, Elahi A, Lazarus P, Tockman MS. (2005a). Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk. Eur J Cancer Prev 14:223-230.
228. Park JY, Chen L, Wadhwa N, Tockman MS. (2005b). Polymorphisms for micro-somal epoxide hydrolase and genetic susceptibility to COPD. Int J Mol Med 15:443-448.
229. Pastorelli R, Guanci M, Cerri A, Negri E, La Vecchia C, Fumagalli F, Mezzetti M, Cappelli R, Panigalli T, Fanelli R, Airoldi L. (1998). Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epox-ide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev 7:703-709.
230. Perera MA, Innocenti F, Ratain MJ. (2008). Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: Are we there yet? Pharmacotherapy 28:755-768.
231. Qu Q, Shore R, Li G, Su L, Jin X, Melikian AA, Roy N, Chen LC, Wirgin I, Cohen B, Yin S, Li Y, Mu R. (2005). Biomarkers of benzene: Urinary metabolites in relation to individual genotype and personal exposure. Chem Biol Interact 153-154:85-95.
232. Raaka S, Hassett C, Omiencinski CJ. (1998). Human microsomal epoxide hydrolase: 5'-Flanking region genetic polymorphisms. Carcinogenesis 19:387-393. (Pubitemid 28375439)
233. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. (1997). Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298-304.
234. Raftogianis RB, Wood TC, Weinshilboum RM. (1999). Human phenol sul-fotransferases SULT1A2 and SULT1A1: Genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol. 58:605-616.
235. Raftogianis R, Creveling C, Weinshilboum R, Weisz J. (2000). Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 27:113-124.
236. Rebbeck TR, Troxel AB, Wang Y, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Bunin G, DeMichele A, Rubin SC, Baumgarten M, Berlin M, Schinnar R, Berlin JA, Strom BL. (2006). Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst 98:1311-1320. (Pubitemid 44530726)
237. Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtrie MW. (2001). Sulfation of thyroid hormone and dopamine during human development: Ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab 86:2734-2742.
238. Riches Z, Bloomer JC, Coughtrie MW. (2007). Comparison of 2-aminophenol and 4-nitrophenol as in vitro probe substrates for the major human hepatic sulfotransferase, SULT1A1, demonstrates improved selectivity with 2-aminophenol. Biochem Pharmacol 74:352-358.
239. Riches Z, Bloomer J, Patel A, Nolan A, Coughtrie M. (2009). Assessment of cryopreserved human hepatocytes as a model system to investigate sul-fation and glucuronidation and to evaluate inhibitors of drug conjugation. Xenobiotica 39:374-381.
240. Robien K, Curtin K, Ulrich CM, Bigler J, Samowitz W, Caan B, Potter JD, Slattery ML. (2005). Microsomal epoxide hydrolase polymorphisms are not associated with colon cancer risk. Cancer Epidemiol Biomarkers Prev 14:1350-1352.
241. Ross D. (2005). Functions and distribution of NQO1 in human bone marrow: Potential clues to benzene toxicity. Chem Biol Interact 153-154:137-146.
242. Ross D, Siegel D. (2004). NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382:115-144.
243. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. (2000). NAD(P) H:quinone oxidoreductase 1 (NQO1): Chemoprotection, bioactivation, gene regulation. Chem Biol Interact 129:77-97.
244. Rossi AM, Guarnieri C, Rovesti S, Gobba F, Ghittori S, Vivoli G, Barale R. (1999). Genetic polymorphisms infuence variability in benzene metabolism in humans. Pharmacogenetics. 9:445-451.
245. Rossi AM, Maggini V, Fredianelli E, Di Bello D, Pietrabissa A, Mosca F, Barale R, Pacifci GM. (2004). Phenotype-genotype relationships of SULT1A1 in human liver and variations in the IC50 of the SULT1A1 inhibitor querce-tin. Int J Clin Pharmacol Ter 42:561-567.
246. Rothman N, Smith MT, Hayes RB, Traver RD, Hoener B, Campleman S, Li GL, Dosemeci M, Linet M, Zhang L, Xi L, Wacholder S, Lu W, Meyer KB, Titenko-Holland N, Stewart JT, Yin S, Ross D. (1997). Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 57:2839-2842.
247. Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A, Gamelin E. (2004). Relevance of diferent UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159.
248. Sabbioni G, Jones CR, Sepai O, Hirvonen A, Norppa H, Järventaus H, Glatt H, Pomplun D, Yan H, Brooks LR, Warren SH, Demarini DM, Liu YY. (2006). Biomarkers of exposure, efect, and susceptibility in workers exposed to nitrotoluenes. Cancer Epidemiol Biomarkers Prev 15:559-566.
249. Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno ?, Ozawa S, Ueno K, Kamakura S, Kamatani N, Komamura K, Kitakaze M, Sawada J (2004). Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048-1054.
250. Sai K, Saito Y, Sakamoto H, Shirao K, Kurose K, Saeki M, Ozawa S, Kaniwa N, Hirohashi S, Saijo N, Sawada J, Yoshida T. (2008). Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 261:165-171.
251. Salama SA, Sierra-Torres CH, Oh HY, Hamada FA, Au WW. (2001). Variant metabolizing gene alleles determine the genotoxicity of benzo[a]pyrene. Environ Mol Mutagen 37:17-26.
252. Sanchez RI, Mesia-Vela S, Kaufman FC. (2003). Induction of NAD(P)H qui-none oxidoreductase and glutathione S-transferase activities in livers of female August-Copenhagen Irish rats treated chronically with estradiol: Comparison with the Sprague-Dawley rat. J Steroid Biochem Mole Biol 87:199-206.
253. Sanderson S, Salanti G, Higgins J. (2007). Joint efects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: A literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol 166:741-751.
254. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Paré PD. (2001). Susceptibility genes for rapid decline of lung function in the lung health study. Am J Resp Crit Care Med 163:469-473.
255. Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB, Kiel S, Geddert H, Kandemir Y, Walter A, Willers R, Gabbert HE. (2003). Association between NAD(P)H:quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 107:381-386.
256. Sarmanová J, Tynková L, Süsová S, Gut I, Soucek P. (2000). Genetic polymorphisms of biotransformation enzymes: Allele frequencies in the population of the Czech Republic. Pharmacogenetics 10:781-788?
257. Sarmanová J, Benesová K, Gut I, Nedelcheva-Kristensen V, Tynková L, Soucek P. (2001). Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin s and non-Hodgkin s lymphomas. Hum Mol Genet 10:1265-1273.
258. Sato K, Iemitsu M, Aizawa K, Ajisaka R. (2008). Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. Am J Physiol Endocrinol Metab 294:E961-E968.
259. Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ. (2003). A pharmacogenetic study of uridine diphosphate-glucuronosyltrans-ferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73:566-574.
260. Schlade-Bartusiak K, Rozik K, Laczmanska I, Ramsey D, Sasiadek M. (2004). Infuence of GSTT1, mEH, CYP2E1 and RAD51 polymorphisms on die-poxybutane- induced SCE frequency in cultured human lymphocytes. Mutat Res 558:121-130.
261. Seth P, Lunetta KL, Bell DW, et al. (2000). Phenol sulfotransferases: Hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 60:6859-6863.
262. Shelby MK, Klaassen CD. (2006). Induction of rat UDP- glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways. Drug Metab Dispos 34:1772-1778.
263. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K. (2004). Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630-2635.
264. Shimada T. (2006). Xenobiotic-metabolizing enzymes involved in activation and detoxifcation of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 21:257-276.
265. Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. (1997). Te reduction of alpha-tocopherolquinone by human NAD(P)H:quinone oxidoreductase: Te role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol 52:300-305.
266. Siegel D, Franklin WA, Ross D. (1998). Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4:2065-2070.
267. Siegel D, McGuinness SM, Winksi SL, Ross D. (1999). Genotype-phenotype Pharmacogenetics 9:113-121.
268. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. (2001). Rapid polyu-biquitination and proteasomal degradation of a mutant form of NAD(P) H:quinone oxidoreductase 1. Mol Pharmacol 59:263-268.
269. Sirma S, Agaoglu L, Yildiz I, Cayli D, Horgusluoglu E, Anak S, Yuksel L, Unuvar A, Celkan T, Apak H, Karakas Z, Devecioglu O, Ozbek U. (2004). NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia. Pediatr Blood Cancer 43:568-570.
270. Smith CA, Harrison DJ. (1997). Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350:630-633.
271. Smith MT, Wang Y, Kane E, Rollinson S, Wiemels JL, Roman E, Roddam P, Cartwright R, Morgan G. (2001). Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97:1422-1426.
272. Smith MT, Wang Y, Skibola CF, Slater DJ, Lo Nigro L, Nowell PC, Lange ?J, Felix CA. (2002). Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 100:4590-4593.
273. Snyder R, Chepiga T, Yang CS, Tomas H, Platt K, Oesch F. (1993). Benzene metabolism by reconstituted cytochromes P450 2B1 and 2E1 and its modulation by cytochrome b5, microsomal epoxide hydrolase, and glutath-ione transferases: Evidence for an important role of microsomal epoxide hydrolase in the formation of hydroquinone. Toxicol Appl Pharmacol 122:172-181.
274. Sorich MJ, Miners JO, McKinnon RA, Smith PA. (2004). Multiple pharmacoph-ores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol.65:301-308.
275. Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, Rajan KB, Porter P, Stanczyk FZ, Ballard-Barbash R, Yuan X, Lin MG, McVarish L, Aiello EJ, McTiernan A. (2004). UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations and tumor receptor status in brease cancer patients. Breast Cancer Res 6:R488-R498.
276. Strassburg CP, Oldhafer K, Manns MP, Tukey RH. (1997). Diferential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identifcation of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
277. Strassburg CP, Nguyen N, Manns MP, Tukey RH. (1999). UDP- glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160.
278. Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. (2002). Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50:851-856.
279. Swanson C, Mellström D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren O, Smith U, Eriksson AL, Bélanger A, Labrie F, Ohlsson C. (2007). Te uridin? diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronida-tion pattern of androgens and fat mass in men. J Clin Endocrinol Metab 92:4878-4882.
280. Tabrett CA, Coughtrie MWH. (2003). Phenol sulfotransferase 1A1 activity in human liver: Kinetic properties, interindividual variation and re-evaluation of the suitability of 4-nitrophenol as a probe substrate. Biochem Pharmacol 66:2089-2097.
281. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y. (2008). Efect of D256N and Y483D on propofol glucuronidation by human uridine 5'-di-phosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol 103:131-136.
282. Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, Mifuji R, Itani T, Kuroda M, Sato H, Kaito M, Adachi Y. (2004a). Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert s syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 19:1023-1028.
283. Takeuchi T, Tsutsumi O, Nakamura N, Ikezuki Y, Takai Y, Yano T, Taketani Y. (2004b). Gender diference in serum bisphenol A levels may be caused by liver UDP-glucuronosyltransferase activity in rats. Biochem Biophys Res Commun 325:549-554.
284. Tang KS, Chiu HF, Chen HH, Eng HL, Tsai CJ, Teng HC, Huang CS. (2005). Link between colorectal cancer and polymorphisms in the uridine- diphosphoglucuronsyltransferase 1A7 and 1A1 genes. World J Gastroenterol 11:3250-3254.
285. Tang KS, Lee CM, Teng HC, Huang MJ, Huang CS. (2008). UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis. Biochem Biophys Res Commun 366:643-648.
286. Taskinen J, Ethell BT, Pihlavisto P, Hood AM, Burchell B, Coughtrie MW. (2003). Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: Structure-Conjugation relationships and predictive models. Drug Metab Dispos 31:1187-1197.
287. Teixeira JP, Gaspar J, Silva S, Torres J, Silva SN, Azevedo MC, Neves P, Lafon B, Méndez J, Gonçalves C, Mayan O, Farmer PB, Ruef J. (2004). Occupational exposure to styrene: Modulation of cytogenetic damage and levels of urinary metabolites of styrene by polymorphisms in genes CYP2E1, EPHX1, GSTM1, GSTT1 and GSTP1. Toxicology 195:231-242.
288. Teixeira JP, Gaspar J, Roma-Torres J, Silva S, Costa C, Roach J, Mayan O, Ruef J, Farmer PB. (2007). Styrene-oxide N-terminal valine haemoglobin adducts in reinforced plastic workers: Possible infuence of genetic polymorphism of drug-metabolising enzymes. Toxicology 237:58-64.
289. Tomae BA, Ecklof BW, Freimuth RR, Wieben ED, Weinshilboum RM. (2002). Human sulfotransferase SULT2A1 pharmacogenetics: Genotype-to-phenotype studies. Pharmacogen J 2:48-56.
290. Tomas SS, Li SS, Lampe JW, Potter JD, Bigler J. (2006). Genetic variability, haplotypes and the htSNPs for exon 1 at the human UGT1A locus. Human Mut 27:717 (1-14).
291. Tiemersma EW, Omer RE, Bunschoten A, van't Veer P, Kok FJ, Idris MO, Kadaru AM, Fedail SS, Kampman E. (2001). Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in afa-toxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 10:785-791.
292. Toncheva DI, Von Ahsen N, Atanasova SY, Dimitrov TG, Armstrong VW, Oellerich M. (2004). Identifcation of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol 17:384-389.
293. Tong Z, Li H, Goljer I, McConnell O, Chandrasekaran A. (2007). In vitro glu-curonidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 35:2203-2210.
294. Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE, Hunter DJ. (2004). Epoxide hydrolase polymorphisms, cigarette smoking and risk of color-ectal adenoma in the Nurses Health Study and the Health Professionals Follow-up Study. Carcinogen 25:1211-1218.
295. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D. (1997). Characterization of a polymorphism in NAD(P)H:quinone oxi-doreductase (DT-diaphorase). Br J Cancer 75:69-75.
296. Tseng CS, Tang KS, Lo HW, Ker CG, Teng HC, Huang CS. (2005). UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol 100:1758-1763.
297. Turgeon D, Carrier JS, Lévesque E, Hum DW, Bélanger A. (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.
298. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. (2007). Infuence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 17:1017-1029.
299. Ulrich CM, Bigler J, Whitton JA, Bostick R, Fosdick L, Potter JD. (2001). Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol Biomarkers Prev 10:875-882.
300. van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, Wobbes T, Nagengast FM, Peters WH. (2006). Role of epoxide hydrolase, NAD(P) H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehy-drogenase genotypes in susceptibility to colorectal cancer. Mutat Res 593:39-49.
301. Vasiliou V, Ross D, Nebert DW. (2006). Update of the NAD(P)H:quinone oxi-doreductase (NQO) gene family. Hum. Genomics 2:329-335.
302. Vest MF (1965). Te development of conjugation mechanisms and drug toxicity in the newborn. Biol Neonat 8:258-266.
303. Vibhuti A, Arif E, Deepak D, Singh B, Qadar Pasha MA. (2007). Genetic polymorphisms of GSTP1 and mEPHX correlate with oxidative stress markers and lung function in COPD. Biochem Biophys Res Commun 359:136-142.
304. Viezzer C, Norppa H, Clonfero E, Gabbani G, Mastrangelo G, Hirvonen A, Celotti L. (1999). Infuence of GSTM1, GSTT1, GSTP1, and EPHX gene polymorphisms on DNA adduct level and HPRT mutant frequency in coke-oven workers. Mutat Res 431:259-269.
305. Vodicka P, Soucek P, Tates AD, Dusinska M, Sarmanova J, Zamecnikova M, Vodickova L, Koskinen M, de Zwart FA, Natarajan AT, Hemminki K. (2001). Association between genetic polymorphisms and biomarkers in styrene-exposed workers. Mutation Res 482:89-103.
306. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, Strassburg CP. (2001). Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 121:1136-1144.
307. Vogel A, Ockenga J, Ehmer U, Barut A, Kramer FJ, Tukey RH, Manns MP, Strassburg CP. (2002). Polymorphisms of the carcinogen detoxifying UDP-glucuronosyltransferase UGT1A7 in proximal digestive tract cancer. Z Gastroenterol 40:497-502.
308. Vogel-Bindel U, Bentley P, Oesch F. (1982). Endogenous role of microsomal epoxide hydrolase. Ontogenesis, induction inhibition, tissue distribution, immunological behaviour and purifcation of microsomal epoxide hydrolase with 16 alpha,17 alpha-epoxyandrostene-3-one as substrate. Eur J Biochem 126:425-441.
309. Voho A, Metsola K, Anttila S, Impivaara O, Järvisalo J, Vainio H, Husgafvel-Pursiainen K, Hirvonen A. (2006). EPHX1 gene polymorphisms and individual susceptibility to lung cancer. Cancer Lett 237:102-108.
310. Walker K, Ginsberg G, Hattis D, Johns, D, Guyton K, Sonawane B. (2009). Genetic polymorphism in N-acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health Part B 12:440-472.
311. Walters JM, Combes RD. (1986). Activation of benzo[a]pyrene and afatoxin B1 to mutagenic chemical species by microsomal preparations from rat liver and small intestine in relation to microsomal epoxide hydrolase. Mutagenesis 1:45-48.
312. Wan J, Shi J, Hui L, Wu D, Jin X, Zhao N, Huang W, Xia Z, Hu G. (2002). Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environ Health Perspect 110:1213-1218.
313. Wang B, Jin F, Xie Y, Tang Y, Kan R, Zheng C, Yang Z, Wang L. (2006). Association analysis of NAD(P)H:quinone oxidoreductase gene 609 C/T polymorphism with Alzheimer s disease. Neurosci Lett 409:179-181.
314. Wang G, Zhang L, Li Q. (2006). Genetic polymorphisms of GSTT1, GSTM1, and NQO1 genes and diabetes mellitus risk in Chinese population. Biochem Biophys Res Commun 341:310-313.
315. Wang J, Huang Y. (2007). Pharmacogenomics of sex diference in chemothera-peutic toxicity. Curr Drug Discov Technol 4:59-68.
316. Wang J, Falany JL, Falany CN. (1998). Expression and characterization of a novel thyroid hormone-sulfating form of cytosolic sulfotransferase from human liver. Mol Pharmacol 53:274-282.
317. Wang Y, Spitz MR, Tsou AM, Zhang K, Makan N, Wu X. (2002). Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: A case-control analysis. Lung Cancer 35:137-142.
318. Wang Y, Kato N, Hoshida Y, Otsuka M, Taniguchi H, Moriyama M, Shiina S, Kawabe T, Ito YM, Omata M. (2004). UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res 10:2441-2446.
319. Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist LE, Wingren S. (2005). Genotype of metabolic enzymes and the beneft of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7: R284-R290.
320. Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S. (2007). Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7 (pp1-9).
321. Wiener D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. (2004a). Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: Importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32:72-79.
322. Wiener D, Fang JL, Dossett N, Lazarus P. (2004b). Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190-1196.
323. Weinshilboum R. (1990). Sulfotransferase pharmacogenetics. Pharmacol Ter 45:93-107.
324. Wenker MA, Kezi? S, Monster AC, de Wolf FA. (2000). Metabolism of styrene-7,8-oxide in human liver in vitro: Interindividual variation and stereochemistry. Toxicol Appl Pharmacol 169:52-58.
325. Wicklife JK, Ammenheuser MM, Salazar JJ, Abdel-Rahman SZ, Hastings-Smith DA, Postlethwait EM, Lloyd RS, Ward JB. (2003). A model of sensitivity: 1,3-Butadiene increases mutant frequencies and genomic damage in mice lacking a functional microsomal epoxide hydrolase gene. Environ Mol Mutage 46:106-110.
326. Wiemels J, Wiencke JK, Varykoni A, Smith MT (1999). Modulation of the toxicity and macromolecular binding of benzene metabolites by NADPH:quinone oxidoreductase in transfected HL-60 cells. Chem Res Toxicol 12:467-475. (Pubitemid 29282916)
327. Wilborn TW, Lang NP, Smith M, Meleth S, Falany CN. (2006). Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. J Steroid Biochem Molec Biol 99:209-214.
328. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, Whittle H, Kirk GD, Hall AJ. (2000). Environmental and genetic determinants of afatoxin-albumin adducts in the Gambia. Int J Cancer 86:1-7.
329. Winski SL, Swann E, Hargreaves RHJ, Dehna DL, Butler J, Moody CJ, Ross D. (2001). Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to anti-tumor quinones. Biochem Pharmacol 61:1509-1516.
330. Winski SL, Koutalos Y, Bentley DL, Ross D. (2002). Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res 62:1420-1424.
331. Xiong Y, Patana AS, Miley MJ, Zielinska AK, Bratton SM, Miller GP, Goldman A, Finel M, Redinbo MR, Radominska-Pandya A. (2008). Te frst aspartic acid if the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucronic acid during catalysis. Drug Metab Dispos 36:517-522.
332. Yang M, Choi Y, Hwangbo B, Lee JS. (2007). Combined efects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer 57:135-142.
333. Yang SP, Wilson K, Kawa A, Raner GM (2006). Efects of green tea extracts on gene expression in HepG2 and Cal-27 cells. Food Chem Toxicol 44:1075-1081.
334. Yang X, Liang S-H, Weyant DM, Lazarus P, Gallagher CJ, Omienski CJ. (2009). T? expression of human microsomal expoxide hydrolase is predominantly driven by a genetically polymorphic far upstream promoter. J Pharmacol Exper Ter 330:23-30.
335. Yasuda S, Liu MY, Suiko M, Sakakibara Y, Liu MC. (2007). Hydroxylated serotonin and dopamine as substrates and inhibitors for human cytosolic SULT1A3. J Neurochem 103:2679-2689.
336. Yin L, Pu Y, Liu TY, Tung YH, Chen KW, Lin P. (2001). Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydro-lase and lung cancer risk in Nanjing, China. Lung Cancer 33:133-141.
337. Yokota H, Iwano H, Endo M, Kobayashi T, Inoue H, Ikushiro S, Yuasa A. (1999). Glucuronidation of the environmental oestrogen bisphenol A by an iso-form of UDP-glucuronosyltransferase, UGT2B1, in the rat liver. Biochem J 340:405-409.
338. Zenser T V, Lakshmi VM, Hsu FF, Davis BB. (2002). Metabolism of N-acetylbenzidine and initiation of bladder cancer. Mutat Res 506-507:29-40.
339. Zhang HP, Varmalova O, Vargas FM, Falany CN, Leyh TS. (1998). Sulfuryl transfer: Te catalytic mechanism of human estrogen sulfotransferase. J Biol Chem 273:10888-10892.
340. Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, Siegel D, Ross D, Gabbert HE, Sarbia M. (2003). Association of NAD(P)H:quinone oxidoreduct-ase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 24:905-909.
341. Zhang Y, Munday R, Jobson HE, Munday CM, Lister C, Wilson P, Fahey JW, Mhawech-Fauceglia P. (2006). Induction of GST and NQO1 in cultured bladder cells and in the urinary bladders of rats by an extract of broccoli (Brassica oleracea italica) sprouts. J Agric Food Chem. 54:9370-9376.
342. Zhang Y, Newcomb PA, Egan KM, Titus-Ernstof L, C?anock S, Welch R, Brinton LA, Lissowska J, Bardin-Mikolajczak A, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Garcia-Closas M. (2006). Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353-358.
343. Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X. (2003). Sulfotransferase 1A1 SULT1A1) polymorphism and bladder cancer risk: A case-control study. Cancer Lett 202:61-69.
344. Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR. (2001). Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:89-94.
345. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. (2001). Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orola-ryngeal cancer risk. J Natl Cancer Inst 93:1411-1418.
346. Zheng Z, Fang JL, Lazarus P. (2002). Glucuronidation: An important mechanism for detoxifcation of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30:397-403.
347. Zimmermann A, Blaszkewicz M, Roth G, Seidel T, Dietrich H, Schutschkow O, Bolt HM, Golka K. (2008). UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism in bladder cancer cases. J Toxicol Environ Health A 71:911-914. (Pubitemid 352000696)